Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-25
2010-11-16
Kosack, Joseph R (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S249000, C514S307000, C514S330000, C514S406000, C544S165000, C544S350000, C546S146000, C546S350000, C548S369400
Reexamination Certificate
active
07834012
ABSTRACT:
The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II, as well as hyperglycemia, metabolic syndrome, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.
REFERENCES:
patent: 3068288 (1962-12-01), Godefroi
patent: 1328935 (1973-09-01), None
patent: 2004/019945 (2004-03-01), None
patent: 2006/009886 (2006-01-01), None
patent: 2006/066770 (2006-06-01), None
Beilstein Institut Zur Forderung der Chemischen Wissenchaften, Tetrahedron Letters 41: 515-520 (2000) XP002416885.
Das, P.C., et al., Indian Journal of Chemistry 12(11): 1139-1140 (1974) XP000864336.
Lowry et al., Journal of Pharmaceuticals Sciences 60(4) 632-633 (1971).
Beilstein Institut Zur Forderung der Chemischen Wissenchaften, Journal Chem. Soc. 2249 Abstract (1961) XP002416886.
Beilstein Institut Zur Forderung der Chemischen Wissenchaften, Indian Journal of Chem. 13: 857 Abstract (1975) XP002416887.
Ponomarev et al., Chem. Abstracts Serv. & Metody Polucheniya Khimicheskikh Reaktivov I Preparatov 17: 165-166 (1968) XP002416888.
Darling et al., Journal of Pharm. Sciences 65: 98-102 (1976) XP002416880.
Ahren, B., BioEssays 20: 642-651 (1998).
Ahren B., et al., Diabetes Care 25: 869-875 (2002).
Barreto-Filho et al., J. Clinical Endocrinol. Metab. 87(5): 2018-2023 (2002).
Bulut, K, et al., “Glucagons-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro—evidence for a TGF-β-mediated effect”, Regulatory Peptides, 2004, 121, 137-143.
Colao et al., “The cardiovascular Risk of Adult GH Deficiencey (GHD) Improved after GH Replacement, et al. ”, J. Clin. Endocrinol. Metab. 87(3): 1088-1093 (2002).
Deacon, et al.,“Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I and rapidly Degraded from the NH sub 2-Terminus in type II Diabetic Patients and Healthy Subjects”, Diabetes 44: 1126-1131 (1995).
Deacon, et al., “Dipeptidyl Peptidase IV Inhibition Potentiates the Insulinotropic Effect of Glucagon-Like Peptide 1 in the Anesthetized Pig”, Diabetes 47: 764-769 (1998).
Drucker, D.J.,, “Glucagon Like Peptides”, Diabetes 47: 159-169 (1998)(abstract only).
Drucker et al., Proc. Natl. Acad. Sci. 93: 7911-7916 (1996).
Flint et al., J. Clin. Invest. 101: 515-520 (1998).
Gotherstrom, et al., J. Clin. Endocrinol. Metab. 86(10): 4657-4665 (2001).
Gutniak et al., Journal of Internal Medicine 250: 81-87 (2001).
Gutzwiller et al., Am. J. Physiol. 276: R1541-R1544 (1999).
Zander et al., Diabetes Care 24: 720-725 (2001).
Jeppesen, P.B., et al., Gut, 2005, 54, 1224-1231.
Johannsson, et al., J. Clin. Endocrinol. Metab. 82(3): 727-734 (1997).
Johannsson, et al., Journal of Endocrinology Investment 22 (5 Supp) 41-46 (1999).
Johannsson et al., Metabolism 44: 1126-1129 1995.
Juntti-Berggren et al., Diabetes Care 19: 1200-1206 (1996).
Karl et al., Physiology and Behavior 80: 123-134 (2003).
Knudsen, et al., Eur. Journal of Pharm. 318: 429-435 (1996).
Kubiak et al., Drug Metab. Dispos. 17: 393-397 (1989).
Kumagai et al., Infection and Immunity 73: 2655-2664 (2005).
Lankas, et al., Diabetes, 2005, 54, 2988-2994.
Lautar et al., Brain Research 1048: 177-184 (2005).
Li, Arch. Biochem. Biophy. 1995, vol. 323, pp. 148-154.
Mentlein, et al., Eur. Journal of Biochemistry 214: 829-835 (1993).
Mentlein, R., Regulatory Peptides 85: 9-24 (1999).
Naslund et al., Am. J. Clin. Nutr. 68: 525-530 (1998).
Nauck, et al. Hormone Metabolism. Res. 29: 411-416 (2002).
Ohnuma et al., J. Immunol. 167(12): 6745-6755 (2001).
Ohtsuki et al., FEBS Lett. 431: 236-240 (1998).
Proost et al., FEBS Letters, 432: 73-76 (1998).
Rachman et al., Diabetologia 40: 205-211 (1997).
Reaven, GM, Physiol. Rev. 75: 473-486 (1995).
Shioda et al., Proc. Natl. Acad. Sci. 95(11): 6331-6336 (1998).
Tanaka et al., Proc. Natl. Acad. Sci. 91: 3082-3086 (1994).
Tanaka et al., Proc. Natl. Acad. Sci. 90: 4583 (1993).
Toft-Nielsen et al., Diabetes Care 22: 1137-1143 (1999).
Backes Bradley J.
Basha Fatima
Judd Andrew S.
Li Xiaofeng
Longenecker Kenton L.
Abbott Laboratories
Kosack Joseph R
Mueller Lisa V.
Polsinelli Shughart PC
LandOfFree
Pharmaceutical compositions as inhibitors of dipeptidyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions as inhibitors of dipeptidyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions as inhibitors of dipeptidyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4218834